Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.11.11 (
AMPK
)
12,425
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
A protein encoded by a new gene with approximately 75% homology to glutamine-fructose-6-phosphate amidotransferase (GFAT) was termed
GFAT2
on the basis of this similarity. The mouse
GFAT2
cDNA was cloned, and the protein was expressed with either an N-terminal glutathione S-transferase or His tag. The purified protein expressed in mammalian cells had GFAT activity. The Km values for the two substrates of reaction, fructose 6-phosphate and glutamine, were determined to be 0.8 mm for fructose 6-phosphate and 1.2 mm for glutamine, which are within the ranges determined for GFAT1. The protein sequence around the serine 202 of
GFAT2
was conserved to the serine 205 of GFAT1, whereas the serine at 235 in GFAT1 was not present in
GFAT2
. Previously we showed that phosphorylation of serine 205 in GFAT1 by the catalytic subunit of
cAMP-dependent protein kinase
(PKA) inhibits its activity. Like GFAT1,
GFAT2
was phosphorylated by PKA, but
GFAT2
activity increased approximately 2.2-fold by this modification. When serine 202 of
GFAT2
was mutated to an alanine, the enzyme not only became resistant to phosphorylation, but also the increase in activity in response to PKA also was blocked. These results indicated that the phosphorylation of serine 202 was necessary and sufficient for these alterations by PKA.
GFAT2
was modestly inhibited (15%) by UDP-GlcNAc but not through detectable O-glycosylation.
GFAT2
is, therefore, an isoenzyme of GFAT1, but its regulation by cAMP is the opposite, allowing differential regulation of the hexosamine pathway in specialized tissues.
...
PMID:Phosphorylation of mouse glutamine-fructose-6-phosphate amidotransferase 2 (GFAT2) by cAMP-dependent protein kinase increases the enzyme activity. 1513 36